strontium-radioisotopes and Carcinoma--Squamous-Cell

Fifteen patients with malignant epithelial tumors of the conjunctiva were treated with beta-ray ocular applicators filled with radioactive strontium and yttrium (90Sr/90Y). Histologic examination confirmed the diagnosis. There were ten squamous cell carcinomas, four carcinomas in situ, and one case of epidermidalization. In one patient, who may have received an insufficient dose, recurrence led to enucleation. Radiogenic complications-secondary glaucoma and corneal degeneration-caused visual loss in two other patients. All of the other tumors disappeared completely without seriously affecting the eyes. Beta-ray irradiation with 90Sr/90Y applicators was effective if a sufficient dose (15,000 to 18,000 rads) was applied to the tumor surface and if the height of the tumor did not exceed 5 mm.

Topics: Adult; Aged; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctiva; Epithelium; Eye Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Radiotherapy; Radiotherapy Dosage; Strontium Radioisotopes; X-Rays; Yttrium Radioisotopes

The observation by Subramanian and his co-workers that a 99mTc-labeled polyphosphate had excellent affinity for bone has led to widespread use of 99mTc-labeled phosphates as bone scanning agents. Initially, only polyphosphate was employed, but because of somewhat inconstant results and difficulty in preparation of this product, other phosphate compounds were sought. We soon discovered that an inorganic compound, pyrophosphate, appeared to have certain advantages over polyphosphate. Other workers formulated diphosphonates (organic phosphates) which also demonstrated advantages over polyphosphates. Comparison studies in rabbits utilizing 85Sr, 87mSr, 18F, and several phosphates (inorganic and organic) proved the 99mTc-labeled phosphates to be clearly superior in delineating normal skeletal anatomy. Studies in humans confirmed that excellent visualization of bone was obtained with 99mTc-labeled phosphates using either a gamma camera or a rectilinear scanner. What was not known, however, was just how reliable this class of agents would prove to be in detecting bone disease when compared to bone-seeking radiopharmaceuticals such as 85Sr, 87mSr, and 18F. Further comparative analyses have clearly demonstrated that both inorganic and organic 99mTc phosphate complexes are extremely sensitive in revealing more bone disease than the older bone scanning agents.

Topics: Adult; Aged; Animals; Bone Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Colonic Neoplasms; Diphosphates; Female; Fluorine; Hodgkin Disease; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Phosphates; Prostatic Neoplasms; Rabbits; Radioisotopes; Radionuclide Imaging; Strontium Radioisotopes; Technetium

The main aim of the study was to establish response, disease-free interval (DFI) and overall survival of cats with nasal planum squamous cell carcinoma (SCC) treated with Sr90 plesiotherapy. A secondary aim was to determine whether a fractionated protocol is more effective than a single-dose protocol in terms of response, DFI and overall survival. The third aim was to evaluate whether we can identify prognostic factors that influence overall survival.. This was a retrospective study that included cats with a diagnosis of nasal planum SCC treated with Sr90 plesiotherapy at a single institution.. Seventy-four cats were included in the study. Thirty-two were treated with a fractionated protocol and 42 with a single-dose treatment. Sr90 plesiotherapy was able to induce complete response in 74% of cats with nasal planum SCC. The median DFI was 780 days (95% confidence interval [CI] 383-1177), with 17% of cats experiencing local recurrence. The overall survival for all cats was 1039 days (95% CI 55-1528). The DFI of cats treated with the fractionated Sr90 was significantly longer compared with the single-dose treatment, whereas response and overall survival were not statistically different. Other prognostic factors that influenced the overall survival were early-stage disease, absence of concurrent problems and complete response to the treatment. Acute and long-term toxicity associated with the treatment were minimal and the aesthetic outcome was pleasing in almost all cases.. Strontium plesiotherapy is a safe and effective treatment of nasal planum SCC in cats.

Topics: Animals; Carcinoma, Squamous Cell; Cat Diseases; Cats; Disease-Free Survival; Dose Fractionation, Radiation; Nose Neoplasms; Retrospective Studies; Strontium Radioisotopes

To report three cases of canine corneal squamous cell carcinoma (SCC) treated with strontium 90 beta radiation as an adjunct to surgical excision.. Corneal SCC was excised with lamellar keratectomy. This was followed by local application of strontium 90 beta radiation.. Available case follow-up times range from 3 to 50 months. One case suffered a recurrence 5 months following initial excision and strontium 90 treatment.. Strontium 90 beta radiation has been used extensively as an adjunctive treatment for equine corneal SCC and in other canine ocular tumors; however, there is a paucity of information regarding use in canine corneal SCC. The cases presented here suggest its use following keratectomy may be helpful in preventing disease recurrence. At the dosage used, severe adverse effects were not observed.

Topics: Animals; Carcinoma, Squamous Cell; Corneal Diseases; Dog Diseases; Dogs; Eye Neoplasms; Male; Strontium; Strontium Radioisotopes

This study explores the safety and efficacy of strontium 90 (Sr-90) brachytherapy as the sole adjuvant therapy for carcinoma in situ (CIS) and squamous cell carcinoma (SCC) of the conjunctiva in a high HIV prevalent area.. This is a retrospective case review of patients treated with 60 Gray Sr-90 brachytherapy in four divided doses after resection with a 2 mm margin and histological confirmation. Cryotherapy or alcohol debridement was not performed at the time of excision due to limited resources. Two plaque sizes, 8.5 mm and 18 mm, were used.. Sixty-nine patients were treated and had a median follow-up of 27 months (range 6-127). Thirty-three (47.8%) were HIV-positive. CIS was present in 40.6% and SCC in 59.4%. The surgical margins were positive in 39 (56.5%). Twenty patients (29.0%) were treated with the 18 mm plaque and 49 (71.0%) with the 8.5 mm plaque. Eight (11.6%) patients developed a recurrence at a median of 5 months (range 2-40). Recurrences only occurred in patients treated with the 8.5 mm plaque (p=0.094). There was no significant effect of HIV status, positive margins or staging on the number of recurrences. Treatment side effects were a dry eye in five patients which was successfully managed with topical lubricants, and induced astigmatism of 1 dioptre of cylinder in one patient.. Sr-90 brachytherapy is safe and effective in preventing recurrences in ocular surface squamous neoplasia in a high HIV prevalent setting. The 18 mm plaque size is superior to the 8.5 mm plaque size.

Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Carcinoma in Situ; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival Neoplasms; Dose Fractionation, Radiation; Female; Follow-Up Studies; HIV Infections; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Strontium Radioisotopes; Young Adult

To determine progression-free and overall survival times of cats with squamous cell carcinoma (SCC) of the nasal planum following treatment with a single fraction of strontium Sr 90 ((90)Sr).. Retrospective case series.. 49 cats with SCC of the nasal planum.. Information including FIV infection status, diagnosis of SCC vs SCC in situ (ie, evidence that the tumor did or did not penetrate the epidermal basement membrane, respectively), (90)Sr dose and number of probe applications, treatment-related response and complications, and recurrence of SCC and new lesion development was obtained from medical records. The relationships of these variables with calculated progression-free and overall survival times were assessed.. Of 49 cats that underwent (90)Sr plesiotherapy (median dose, 128 Gy), 48 (98%) had a response to treatment and 43 (88%) had a complete response. Median progression-free and overall survival times were 1,710 and 3,076 days, respectively. Treatment complications were infrequent (4 [8%] cats) and mild. Following treatment, the SCC recurrence rate was 20% (10/49 cats); 16 (33%) cats developed new lesions in other locations. Overall survival time was significantly longer for cats with a complete response to treatment than for those with a partial response. None of the other variables evaluated had a significant effect on progression-free or overall survival time.. Treatment of cats with SCC of the nasal planum with a single fraction of (90)Sr appeared to be effective and well tolerated. Initial response to treatment was predictive of overall survival time.

Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Disease-Free Survival; Dose-Response Relationship, Radiation; Female; Male; Nose Neoplasms; Radiotherapy Dosage; Retrospective Studies; Strontium Radioisotopes; Treatment Outcome

The responses of 15 cats with histologically (n=14) or cytologically (n=1) confirmed nasal squamous cell carcinoma treated with (90)Strontium plesiotherapy were reviewed retrospectively. Cats were treated such that a total dose of 50Gy was delivered at a depth of 2mm, administered in five fractions over a 10-day period. Of the cats, 11 were stage T(2), three were T(is) and one had only a cytological diagnosis precluding staging. Eleven of the cats achieved complete response (no visible lesion after 6-8 weeks) following the first cycle of therapy, and two cats with partial response achieved complete response with a second cycle of therapy. The remaining two cats achieved partial response following therapy, but further intervention was declined. Euthanasia was performed in these two cats because of progressive disease after 81 and 142 days. Of the 85% of cats that achieved a complete response, there was no recurrence of disease during a follow-up period of 134-2,043 days (median 652 days). In addition to prolonged disease-free survivals, (90)Strontium therapy produced excellent cosmetic results from the owners' perspective. These results demonstrate that superficial squamous cell carcinoma of the feline nasal planum responds excellently to (90)Strontium plesiotherapy, and this form of therapy may offer advantages over other alternatives currently available.

Topics: Animals; Carcinoma, Squamous Cell; Cat Diseases; Cats; Dose-Response Relationship, Radiation; Female; Male; Nose Neoplasms; Radiotherapy Dosage; Retrospective Studies; Strontium Radioisotopes; Treatment Outcome

To investigate the therapeutic effects of strontium-89 against osseous metastases of lung cancer.. A total of 126 patients with osseous metastases of lung cancer received strontium-89 treatment ((89)SrCl(2)) at the dose of 148 MBq given through a single intravenous injection. The analgesic effect was evaluated by the changes in the degree, frequency and scores of the pain, and the therapeutic effect assessed by observing the changes in the number and volume of osseous lesions after therapy and compared between different pathological types of lung cancer by Ka-square test.. Within 6 months after the injection, the total pain relief rate was 70.6% (89/126), including 25 (19.8%) cases with pain vanished, suggesting significant alleviation of the pain intensity by the treatment (u=5.361, P<0.01). The frequency of pain was reduced in 78.6% (99/126) of the cases (u=4.589, P<0.01), and the average score of pain decreased significantly from 7.54+/-3.29 to 4.19+/-4.38 (t=6.865, P<0.001). The number and size of lesions decreased by more than 25% in 57 cases, showing a total efficacy rate of 45.2% (57/126). No significant difference was noted in the therapeutic effects among the 4 pathological types of lung cancer (P>0.05).. Strontium-89 is effective for pain relief and tumor focus confinement in osseous metastases of lung cancer. No significant difference has been found in its effect between 4 different pathological types of lung cancer.

Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pain, Intractable; Strontium Radioisotopes

We report two cases of children with metastatic bone disease who received strontium-89 intravenously. An 11-year-old boy with stage IV neuroblastoma received 50 microCi/kg of strontium-89. He had a good response, and his pain abated to the point that he could be taken off IV Dilaudid and was discharged from the hospital. A 7-year-old girl with the diagnosis of squamous cell carcinoma of the lung disclosed minimal increased uptake on a bone scan. Following the strontium-89 therapy, she did not have any significant improvement in pain, probably due to the minimal osteoblastic activity evidenced by the minimal abnormalities on the bone scan. Until this report there has been no reported case of using strontium-89 in the treatment of children with metastatic disease.

Topics: Analgesics, Opioid; Bone Neoplasms; Carcinoma, Squamous Cell; Child; Cranial Irradiation; Fatal Outcome; Female; Humans; Hydromorphone; Injections, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Neuroblastoma; Osteoblasts; Pain; Palliative Care; Patient Discharge; Remission Induction; Spinal Cord; Strontium Radioisotopes

Clonal origin of skin and bone tumors produced by repeated beta-irradiation was determined by using mice with cellular mosaicism created by random X-chromosome inactivation, on the basis of phosphoglycerate kinase-1 (PGK). The backs of female C3H/He (Pgk-1a/Pgk-1b) mice were exposed to beta rays from 90Sr-90Y at a dose of 3 Gy per exposure 3 times weekly until tumors appeared. The cumulative tumor incidence reached 100% 500 days after the beginning of irradiation, as determined by the Kaplan-Meier method. All 8 tumors examined were of a single PGK phenotype: 5 squamous cell carcinomas and 2 osteosarcomas of A-type, and 1 squamous cell carcinoma of B-type. The absence of double PGK phenotype (AB-type) tumors indicated the monoclonal origin of the tumors produced by repeated irradiation.

Topics: Animals; Beta Particles; Bone Neoplasms; Carcinoma, Squamous Cell; Dosage Compensation, Genetic; Female; Mice; Mice, Inbred C3H; Mosaicism; Neoplasms, Radiation-Induced; Osteosarcoma; Phosphoglycerate Kinase; Skin Neoplasms; Strontium Radioisotopes; Yttrium Radioisotopes

Twenty-seven patients with malignant epithelial tumors of the conjunctiva were treated between 1967 and 1987. Histological diagnosis was intraepithelial epithelioma in 15 cases (56%) and squamous cell carcinoma in 12 (44%). All patients were treated with a strontium-90 source on cup-shaped applicators of different sizes according to the extension of the tumor. Surface dose ranged from 60 Gy in a single treatment to 140 Gy in 7 fractions, depending on the thickness of the lesion. Fifteen patients were previously untreated, 7 were irradiated after some type of surgical treatment and 5 were treated for recurrence after multiple surgical excisions. Follow-up period ranged from 2 to 15 years. No patient died of his tumor. There were four local recurrences, three of them in patients with intraepithelial carcinoma. Two of the recurrences were salvaged with a new beta-ray treatment and the other two with enucleation. Since 1981, standard policy was to irradiate the entire conjunctiva in patients with diagnosis of intraepithelial epithelioma. Five patients developed cataracts. Considering the high primary control rate and minimal morbidity, strontium irradiation should be considered as a first-choice treatment for conjunctival tumors.

Topics: Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Eye Enucleation; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Strontium Radioisotopes

Squamous cell carcinoma of the ocular conjunctiva is a relatively rare malignancy which is attended by a high rate of local recurrence following simple surgical excision. To date, the management of conjunctival squamous cell cancer has been controversial. From 1950 to 1985, 146 consecutive patients with superficial conjunctival squamous cell cancer were treated at the Queensland Radium Institute. All patients were treated by simple surgical excision of the visible conjunctival lesion followed by adjunctive radiotherapy. Of 140 patients with histologically confirmed squamous cell cancer, 123 were treated with a strontium-90 source, 10 with a radon "ring," and 7 with superficial X ray therapy. Standard policy since 1960 has been to deliver an incident dose of 30 Gy in a single fraction within the first 48 post-operative hours to the surgical bed using a strontium-90 source on a stand-off eye applicator. This report will largely focus on the 123 patients who were treated with a strontium-90 source, of whom 107 received 30 Gy, 14 received 40 Gy (pre 1960) and one patient each received 20 and 25 Gy incident dose. Of 131 evaluable patients, there were only 3 who developed local recurrence. All 3 local recurrences developed in elderly men who had presented with extensive superficial primary tumors. Two of the three recurrences occurred in the two patients who were treated with doses less than 30 Gy. Both early and late radiation-induced complications following ablative surgery and treatment with strontium-90 were very uncommon. Three patients developed unsightly conjunctival telangiectasia, 2 patients developed a persistent scleral ulcer and 2 patients developed clinically significant cataracts. This negligible degree of treatment-related side effects contrasts with the experience of 10 patients who had previously been treated with a radon ring, 8 of whom developed serious complications, although none developed local recurrence. On the basis of our excellent local control rates with minimal morbidity we would continue to advocate the use of simple surgical excision followed by 30 Gy beta radiation from a strontium-90 source as the definitive treatment for superficial conjunctival squamous cell cancer.

Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Conjunctival Neoplasms; Female; Humans; Male; Middle Aged; Strontium Radioisotopes

A 87-year-old female patient with a squamous cell carcinoma of the conjunctiva was treated with local strontium-90 irradiation (with a so-called 'Dermaplatte'). In spite of a relatively low dosage, radiotherapy was followed by a corneal ulcer with consecutive rupture of the cornea. The cause of this unexpected perforation was, besides the effect of low-dose irradiation, probably a metabolic disorder of the cornea and a disturbance of the tear film due to the carcinoma which had spread on Bowman's layer of the cornea in an exophytic manner and was accompanied by a dense lymphocytic infiltration. An exenteration was performed and, at the last examination (1 year later), no local recurrence could be detected.

Topics: Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Conjunctival Neoplasms; Cornea; Corneal Ulcer; Female; Humans; Rupture, Spontaneous; Strontium Radioisotopes

We present the first detailed dose-response measurements for 90Sr-induced soft tissue tumors other than hemopoietic dyscrasias in chronically exposed beagles. Twenty-four of 387 dogs exposed to 90Sr beginning in utero and by continuous ingestion to 540 days of age developed squamous cell carcinoma of the jaw during their lifetime. Eleven of the 24 tumors were observed in dogs ingesting 12 microCi/day and receiving cumulative average doses of 6500-12,000 rad. None of these tumors was observed in dogs ingesting less than 1.25 microCi/day and receiving cumulative skeletal average doses of 2100-3900 rad, but four were observed at this level. The teeth of these animals acquired a 90Sr burden that is not removed by skeletal remodeling. Measurements of the radiation dose to soft tissue adjacent to the mandible and teeth of dogs chronically fed 90Sr indicated the first 10 micron of soft tissue adjacent to teeth received a radiation dose initially about the same as the average skeletal doses. By 2000-3000 days, these tissues received about two to three times that calculated for the average skeletal dose, or about four to six times the mean marrow dose. We suggest that these tumors arise from epithelial rests, which are embryonic tissue trapped in the periodontal membrane between teeth and bone.

Topics: Administration, Oral; Animals; Body Burden; Carcinoma, Squamous Cell; Dogs; Female; Jaw Neoplasms; Mandible; Neoplasms, Radiation-Induced; Pregnancy; Prenatal Exposure Delayed Effects; Radiation Dosage; Strontium Radioisotopes; Tooth

Topics: Animals; Carcinoma, Squamous Cell; Eyelid Neoplasms; Horse Diseases; Horses; Nictitating Membrane; Strontium Radioisotopes

Beagles were exposed by inhalation to relatively soluble forms of single beta-emitting radionuclides and are being held for life-span observation to evaluate biologic hazards associated with nuclear power production. The dogs were exposed to graded activity levels of 91YCl3, 144CeCl3, or 90SrCl2. With 91YCl3 and 144CeCl3, a significant radiation dose was delivered to the respiratory tract, liver, and skeleton. With 90SrCl2, the dose was almost totally to the skeleton. Squamous cell carcinomas associated with the nasal cavity have been the most frequently observed neoplasms in the 91YCl3 study and one of the most frequent in the 144CeCl3 study, whereas few squamous cell carcainomas have been seen in the 90SrCl2 study. One hemanglosarcoma in the nasal cavity was also seen in the 144Ce study. The incidence of nasal carcinomas may be related to higher relative concentrations of the radionuclides 91Y and 144Ce associated with the nasal turbinates. This relatively high risk of nasal cavity neoplasms suggests that standards for human exposure to these radionuclides should included a consideration of the nasal cavity epithelium as a major target tissue.

Topics: Air Pollutants; Air Pollutants, Radioactive; Animals; Carcinoma, Squamous Cell; Cerium Radioisotopes; Dogs; Dose-Response Relationship, Radiation; Nasal Cavity; Neoplasms, Radiation-Induced; Nose Neoplasms; Strontium Radioisotopes; Yttrium Radioisotopes

Close relation of non osseus facial skull portions to the skeleton cause rapidly the bone to become co-involved in presence of various diseases. Early diagnosis is of decisive importance for therapeutic measures. For localisation scintigraphy has proved particularly reliable in aids to early determination. This can be shown clearly in inflammatory diseases and tumour infiltrations with various tumour affections. Technical requirements and the use of skeletal scinitgraphy are demonstrated on hand of 6 cases.

Topics: Adult; Aged; Carcinoma, Squamous Cell; Child; Cholesterol; Female; Fluorine; Granuloma; Humans; Male; Maxillary Neoplasms; Middle Aged; Osteitis Deformans; Otorhinolaryngologic Diseases; Posture; Radioisotopes; Radionuclide Imaging; Sinusitis; Skull; Strontium Isotopes; Strontium Radioisotopes; Technetium

The use of strontium 90 has proved to be efficient and practical, because handy, and permitting short treatment, not only, to cure benign superficial tumors and, as reported in this study, of pre-cancerous lesions such as actinic keratosis, Bowen's disease of the skin but also some carefully chosen cases of superficial carcinomas. Hundred lesions have been so treated and followed for 3 years; two only have relapsed. The cosmetic result has been excellent in 80 p. 100.

Topics: Aged; Bowen's Disease; Carcinoma, Squamous Cell; Drug Evaluation; Female; Humans; Keratosis; Male; Precancerous Conditions; Radiotherapy; Radiotherapy Dosage; Skin Neoplasms; Strontium Radioisotopes

Beta-emitting radionuclides are important constituents of isotope inventories in light water reactors and may pose an inhalation hazard to industrial workers or the general population if they are released. To study the biological effects of such potential exposures, a series of life span studies was initiated in which beagle dogs were exposed to aerosols of relatively insoluble fused clay particles containing 90Y, 91Y, 144Ce or 90Sr. Groups of dogs exposed to each radionuclide received graded initial lung burdens of radioactivity. When combined with the varied physical half-lives of the four radionuclides, this resulted in a wide variety of radiation doses and dose patterns to the lung. Deaths (greater than 640 days after exposure) were generally associated with pulmonary neoplasia in dogs that inhaled 91Y, 144Ce or 90Sr. These dogs had cumulative lung doses to death greater than 20 000 rads. Exposure to 144Ce or 90Sr with dose rates that decreased slowly induced pulmonary haemangiosarcomas. Pulmonary irradiation from 91Y, with a rapidly decreasing dose rate, resulted in pulmonary epithelial tumours. No malignant lung tumours have been seen within 1540 days after exposure to 90Y. The animals in the main studies have been observed for 1342 to 2756 days after exposure.

Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aerosols; Animals; Carcinoma, Squamous Cell; Cerium Radioisotopes; Dogs; Female; Fibrosarcoma; Hemangiosarcoma; Lung Neoplasms; Male; Neoplasms, Experimental; Neoplasms, Radiation-Induced; Radiation Dosage; Strontium Radioisotopes; Time Factors; Yttrium Radioisotopes

An electron microscopic study was performed on a conjunctival squamous cell carcinoma in an 82-year-old man. Biopsies were taken before and during beta-irradiation and the morphologic features of nonirradiated tumor cells were compared to those after application of 10,000 rad. There occur striking changes in the nucleus and the cytoplasm after irradiation. The nuclei show hypertrophic and electron-dense nucleoli as well as altered chromatin structures. The cytoplasm of many cells appears destroyed and contains numerous vacuole-like structures, as well as swollen mitochondria. It is of interest that numerous normal lymphoid cells were present within the irradiated tumor.

Topics: Aged; Carcinoma, Squamous Cell; Cell Nucleolus; Cell Nucleus; Conjunctiva; Desmosomes; Endoplasmic Reticulum; Eye Neoplasms; Humans; Male; Mitochondrial Swelling; Strontium Radioisotopes; Vacuoles; Yttrium Radioisotopes

Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Squamous Cell; Child, Preschool; Diagnosis, Differential; Humans; Lymphatic Metastasis; Male; Maxillary Neoplasms; Plasmacytoma; Postoperative Care; Preoperative Care; Prognosis; Radioisotope Teletherapy; Radionuclide Imaging; Radiotherapy Dosage; Sarcoma; Strontium Radioisotopes

Topics: Animals; Carcinoma, Squamous Cell; Fibrosarcoma; Mice; Neoplasms, Experimental; Phosphorus; Phosphorus Radioisotopes; Sarcoma, Experimental; Skin; Skin Neoplasms; Strontium; Strontium Radioisotopes

Topics: Animals; Bronchi; Carcinoma; Carcinoma, Squamous Cell; Epithelium; Lung Neoplasms; Radiation Injuries; Radiation Injuries, Experimental; Rats; Strontium; Strontium Radioisotopes

Topics: Animals; Carcinoma, Squamous Cell; Epithelium; Lung Neoplasms; Neoplasms, Experimental; Radiation Injuries, Experimental; Rats; Strontium; Strontium Radioisotopes